But from the data published, the interim data published last year and updated even recently this year, we are confident that the signal is present actually when K3DL2 is expressed. And hence, the potential for lacutamab to be used in the treatment of peripheral T-cell lymphoma. I remind you that almost half of the patients with PTCL do express K3DL2. We are running two trials in the difficult-to-treat relapsed/refractory setting. One is a company-sponsored trial. It’s mainly a safety Phase 1b trial that we are conducted and for which we will present an update in a couple of weeks at ASH. And the second trial is an investigator-sponsored trial performed in collaboration with the Liza Group, and it’s a combination trial. And I think the combination strategy in particularly in the relapse refractory is something very important.
We are, of course, excited by the preclinical data that we have generated and that we will be published at ASH, as I said, in a couple of weeks. We remain optimistic about the potential to run combination trials in the relapse refractory setting, but also in first line. And the plan, of course, is to expand the development of lacutamab in peripheral T-cell lymphoma beyond the difficult-to-treat relapsed/refractory, but that’s the first step.
Jingming Chen: Got it. Thank you.
Operator: There are no further questions at this time. I would now like to turn the call over to Mondher Mahjoubi for closing remarks.
Mondher Mahjoubi: Thank you. As a concluding remark, I would say, A, we are very encouraged by the robust outcomes or lacutamab in heavily pretreated patient with Sezary syndrome. Our discussions with the FDA will enable us to evaluate the potential for accelerated approval and to firm up Phase 3 plans. We are, of course, an ongoing dialogue with potential partners that can realize the full potential of the drug for patients with T-cell lymphoma, both cutaneous and peripheral T-cell lymphoma. Second message, we are making great progress with our early stage pipeline. Pleased to see the progress of IPH61 or SAR’579 in AML with an update at the upcoming ASH. Pleased to announce that we have cleared the IND for IPH65, and we are waiting for the start of the Phase 1 this year.
And finally, as you’ve heard from Yannis, excited by our differentiated anti-Nectin-4 ADC with a top one payload, which is moving towards IND next year. Last but not least, sufficient cash to fund operation into H2 next year with – as of end of September, €122 million, ’25 – sorry, yes, fund cash in H2 2025. Thank you very much.
Operator: I would like to thank our speakers for today’s presentation, and thank you all for joining us. This now concludes today’s call, and you may now disconnect.
